newsfilter
← Latest News
Business Wire·

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

  • bioAffinity Technologies will sponsor a CHEST 2026 Learning Theater presentation on October 21, 2026, featuring Chief Medical Officer Gordon Downie, MD, PhD.
  • The presentation will address challenges in pulmonary nodule management & discuss preliminary data on an investigational test for asthma & COPD-related lung inflammation.
  • Dr. Downie will examine how CyPath® Lung uses lung microenvironment analysis to improve lung cancer risk stratification & aid decisions on biopsy or surveillance.
  • CyPath® Lung is a noninvasive sputum test utilizing flow cytometry & AI to detect malignancy, showing 92% sensitivity & 99% negative predictive value in prior clinical trials.
  • The company's Medical & Scientific Advisory Board will convene at the conference to discuss CyPath® Lung's expansion into the federal healthcare system & ongoing longitudinal studies.
  • Advisory Board members include experts from the American Lung Association, MD Anderson Cancer Center, NYU Langone Medical Center, & other leading pulmonary institutions.
  • CyPath® Lung is marketed as a Laboratory Developed Test (LDT) under CLIA regulations & is not intended to be used as a sole diagnostic tool.